Pulmatrix Inc Stock

$7.00

0.72% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US74584P1030

Symbol

PULM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Pulmatrix Inc Stock price

$7.00

-29.60 80.87% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.05 0.72%

ISIN

US74584P1030

Symbol

PULM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$25.6m

Enterprise Value

$17.9m

Net debt

$-7.7m

Cash

$7.7m

Shares outstanding

3.7m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

13.32 | 3.58

EV/Sales

9.30 | 2.50

EV/FCF

negative

P/B

3.58

Financial Health

Equity Ratio

89.98%

Return on Equity

-106.84%

ROCE

-172.83%

ROIC

2,873.72%

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$1.9m | $7.1m

EBITDA

$-12.0m | -

EBIT

$-12.4m

Net Income

$-12.2m | $-18.4m

Free Cash Flow

$-10.1m

Growth (TTM | estimate)

Revenue

-83.56% | -8.51%

EBITDA

-29.51% | -

EBIT

-31.35%

Net Income

-37.74% | -92.78%

Free Cash Flow

31.16%

Margin (TTM | estimate)

Gross

EBITDA

-623.69% | -

EBIT

-643.26%

Net

-634.67% | -257.93%

Free Cash Flow

-523.37%

EPS

$-3.34

FCF per Share

$-2.75

Short interest

0.85%

Employees

2.00

Rev per Employee

$3.91m

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Pulmatrix Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Pulmatrix Inc forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Pulmatrix Inc forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Pulmatrix Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	1.92 1.92	84% 84% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	7.99 7.99	35% 35% 416%
- Research and Development Expense	3.67 3.67	76% 76% 191%
EBITDA	-12 -12	30% 30% -624%
- Depreciation and Amortization	0.38 0.38	138% 138% 20%
EBIT (Operating Income) EBIT	-12 -12	31% 31% -644%
Net Profit	-12 -12	38% 38% -635%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Pulmatrix Inc Stock News

Neutral

PRNewsWire

●

about one month ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

Registration statement for proposed Cullgen merger declared effective by the SEC Proposed merger anticipated to close in June As part of proposed merger, Pulmatrix currently intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass. , May 15, 2025 /PRNewswire/ -- Pulmatrix, Inc. ...

Neutral

Business Wire

●

about 2 months ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pulmatrix, Inc. (NasdaqCM: PULM) and Cullgen Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Pulmatrix stockholders are expected to own approximately 3.6% of the combined company. KSF...

Neutral

PRNewsWire

●

3 months ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Announced merger agreement with Cullgen in November, anticipated to close in the first half of 2025 As part of proposed merger, Pulmatrix intends to divest its assets including its Phase 2-ready acute migraine candidate, PUR3100, and other development candidates based on its iSPERSE™ technology FRAMINGHAM, Mass. , March 21, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Na...

Company Profile

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.

Head office	United States
CEO	Peter Ludlum
Employees	2
Founded	2015
Website	www.pulmatrix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now